Related Experiment Video
Updated: Mar 14, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.6K
Therapeutic options for psoriasis: Review and update
1UCSF Psoriasis Treatment Center, San Francisco, California, USA.
Saudi Medical Journal
|October 5, 2016
Summary
This study is unavailable in digital format. The full text can only be accessed as a scanned copy of the original print version.
Area of Science:
- This study falls under the category of general medicine and scientific research accessibility.
Background:
- The full text of this research paper is not available in a digital format.
- Access is limited to a scanned copy of the original print version.
Purpose of the Study:
- To inform researchers and readers about the accessibility status of the full text.
- To guide users on how to access the available version of the research.
Main Methods:
- The study's methodology is not detailed as it pertains to the accessibility of the full text.
- Information is provided regarding the format in which the full text is available.
Main Results:
- The full text is exclusively available as a scanned copy of the original print version.
- No digital or other formats of the full text are currently provided.
Conclusions:
- Researchers and readers must be aware that only a scanned print version is accessible.
- Alternative access methods or formats are not currently offered for this publication.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
893
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
893
01:24T Cell Types and Functions
3.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.1K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
693
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
693
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
593
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
593
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
636
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
636